rifapentine + midazolam

Rifapentine + midazolam is a combination of two pharmaceutical agents with distinct mechanisms and indications. Rifapentine is an antibiotic in the antimycobacterial class used primarily for the treatment of active and latent tuberculosis, often in combination with other antitubercular drugs. It acts by inhibiting bacterial RNA synthesis through binding to the beta subunit of DNA-dependent RNA polymerase, thereby killing or preventing the growth of Mycobacterium tuberculosis[2][8]. Midazolam is a short-acting benzodiazepine used as a sedative, anxiolytic, muscle relaxant, anticonvulsant, and hypnotic agent. Its primary mechanism involves positive allosteric modulation of GABA-A receptors in the central nervous system to enhance inhibitory neurotransmission[1][3][4]. Notably, co-administration can result in significant drug-drug interactions; rifapentine (like its analog rifampin) induces CYP3A4 enzymes that metabolize midazolam—markedly reducing plasma concentrations and pharmacodynamic effects of midazolam[5].